| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/05/2011 | EP2270211A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270210A2 Method for diagnosing non-small cell lung cancers |
| 01/05/2011 | EP2270209A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 01/05/2011 | EP2270177A1 Streptococcus pneumoniae proteins and nucleic acids |
| 01/05/2011 | EP2270176A1 Streptococcus pneumoniae proteins and nucleic acids |
| 01/05/2011 | EP2270175A1 Streptococcus pneumoniae proteins and nucleic acids |
| 01/05/2011 | EP2270174A1 Combination neisserial compositions |
| 01/05/2011 | EP2270173A1 Combination neisserial compositions |
| 01/05/2011 | EP2270172A1 Combination neisserial compositions |
| 01/05/2011 | EP2270171A2 Haemophilus influenzae antigens and corresponding DNA fragments |
| 01/05/2011 | EP2270170A1 Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
| 01/05/2011 | EP2270169A2 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| 01/05/2011 | EP2270164A2 Recombinant protein variants |
| 01/05/2011 | EP2270150A2 Method for controlling the activity of immunologically functional molecule |
| 01/05/2011 | EP2270149A2 Method for controlling the activity of immunologically functional molecule |
| 01/05/2011 | EP2270148A2 Method for controlling the activity of immunologically functional molecule |
| 01/05/2011 | EP2270147A2 Method for controlling the activity of immunologically functional molecule |
| 01/05/2011 | EP2270144A1 Partial peptide of survivin presented on mhc class ii molecule and use thereof |
| 01/05/2011 | EP2270054A2 Anti-idiotype antibodies of the human monoclonal antibody SC-1, and their production and use |
| 01/05/2011 | EP2270053A1 Humanized AXL antibodies |
| 01/05/2011 | EP2270052A2 Antibodies to OPGL |
| 01/05/2011 | EP2270051A2 Antibody specific for human PD-1 and CD3 |
| 01/05/2011 | EP2270050A1 Anti-CD19 antibodies with reduced immunogenicity |
| 01/05/2011 | EP2270049A2 Recombinant anti-interleukin-9-antibody |
| 01/05/2011 | EP2270048A2 Anti-NGF antibodies and methods using same |
| 01/05/2011 | EP2270047A2 Anti-C5 antibodies and their therapeutic uses |
| 01/05/2011 | EP2270046A2 Methods and compositions for the treatment of hemolysis-associated diseases |
| 01/05/2011 | EP2270045A1 Antibodies against Clostridium difficile toxins and uses thereof |
| 01/05/2011 | EP2270044A1 Liquid immunoglobulin G (lgG) product |
| 01/05/2011 | EP2270042A2 KDR peptides and vaccines comprising the same |
| 01/05/2011 | EP2270041A2 KDR peptides and vaccines comprising the same |
| 01/05/2011 | EP2270032A2 Outer membrane protein of Ehrlichia canis and Ehrlichia chaffeenis |
| 01/05/2011 | EP2270031A2 Heterologous expression of neisserial proteins |
| 01/05/2011 | EP2270030A2 Heterologous expression of Neisserial proteins |
| 01/05/2011 | EP2269656A2 Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment |
| 01/05/2011 | EP2269644A2 Microfluidized oil-in-water emulsions and vaccine compositions |
| 01/05/2011 | EP2269643A2 Hcv vaccine compositions |
| 01/05/2011 | EP2269642A2 Hcv vaccine compositions |
| 01/05/2011 | EP2269641A2 Hcv vaccine compositions |
| 01/05/2011 | EP2269640A2 Hcv vaccine compositions |
| 01/05/2011 | EP2269639A2 Influenza vaccine formulations for intradermal delivery |
| 01/05/2011 | EP2269638A2 Vaccine compositions comprising virosomes and a saponin adjuvant |
| 01/05/2011 | EP2269637A1 Influenza Vaccine |
| 01/05/2011 | EP2269636A2 Chlamydia trachomatis antigens for vaccine and diagnostic use |
| 01/05/2011 | EP2269635A1 Enterococcus antigens and vaccines |
| 01/05/2011 | EP2269634A2 Antigenic polypeptides |
| 01/05/2011 | EP2269633A1 Peptide conjugate compositions and methods for the prevention and treatment of Alzheimer's disease |
| 01/05/2011 | EP2269632A2 Immunostimulatory compositions and methods of stimulating an immune response |
| 01/05/2011 | EP2269630A1 Novel anti-nematode therapies targetting STRM-1 |
| 01/05/2011 | EP2269619A1 Methods and compositions concerning poxviruses and cancer |
| 01/05/2011 | EP2269618A1 An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer. |
| 01/05/2011 | EP2269616A2 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| 01/05/2011 | EP2269597A1 CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis |
| 01/05/2011 | EP2268801A2 Compositions and processes relating to human bocavirus |
| 01/05/2011 | EP2268672A1 Anti-tyrp1 antibodies |
| 01/05/2011 | EP2268671A1 Novel antibodies used to treat cancer |
| 01/05/2011 | EP2268670A1 Glucagon receptor antagonists |
| 01/05/2011 | EP2268669A1 Immuno-modulating compositions for the treatment of immune-mediated disorders |
| 01/05/2011 | EP2268664A2 Doc1 compositions and methods for treating cancer |
| 01/05/2011 | EP2268659A2 Mutant forms of chlamydia htra |
| 01/05/2011 | EP2268310A1 Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas |
| 01/05/2011 | EP2268309A2 Improvements in preparation of influenza virus vaccine antigens |
| 01/05/2011 | EP2268308A2 Vaccine for protection against lawsonia intracellulars |
| 01/05/2011 | EP2268307A1 Vaccine |
| 01/05/2011 | EP2268306A2 Therapeutic cancer antigens |
| 01/05/2011 | EP2268305A2 Oxidized paraoxonase 1 and paraoxonase 1/hdl particle number ratio as risk markers for cardiovascular disease |
| 01/05/2011 | EP2268297A1 Modified toxins |
| 01/05/2011 | EP2268289A1 Anti-infective agents and uses thereof |
| 01/05/2011 | EP2069404B1 Humanized anti-cd100 antibodies |
| 01/05/2011 | EP1922334B1 Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine |
| 01/05/2011 | EP1720572B1 Monovalent ligand of the fcalphari receptor as an anti-inflammatory agent |
| 01/05/2011 | EP1603941B1 Inhibitors of extracellular hsp90 |
| 01/05/2011 | EP1546182B1 Compositions and methods for the diagnosis and treatment of tumor |
| 01/05/2011 | EP1485415B1 Neoplasm specific antibodies and uses thereof |
| 01/05/2011 | EP1453471B1 Expression vectors encoding epitopes of antigens and methods for their design |
| 01/05/2011 | EP1334197B1 Yeast derived vaccine against ipnv |
| 01/05/2011 | EP1317484B2 Variants of the phleum pratense phl p 1 allergenic protein |
| 01/05/2011 | EP1301202B1 Genetically-engineered mhc molecules |
| 01/05/2011 | EP0815129B1 Ingap protein involved in pancreatic islet neogenesis |
| 01/05/2011 | CN1968711B Combination vaccines with low dose of HIB conjugate |
| 01/05/2011 | CN1878562B Antibody therapy |
| 01/05/2011 | CN1802388B CD20-specific antibodies and methods of employing same |
| 01/05/2011 | CN101939438A Vaccine |
| 01/05/2011 | CN101939425A Anti-IL-6 receptor antibody |
| 01/05/2011 | CN101939424A Anti-nr10 antibody and use thereof |
| 01/05/2011 | CN101939419A Recombinant BCG tuberculosis vaccine for eliciting immune responses to mycobacterium tuberculosis |
| 01/05/2011 | CN101939338A 1b20 pcsk9 antagonists |
| 01/05/2011 | CN101939337A Anti-TRKA antibodies and derivatives thereof |
| 01/05/2011 | CN101939336A AXL antibodies |
| 01/05/2011 | CN101939335A Antigen-binding polypeptides against cartilage degeneration |
| 01/05/2011 | CN101939333A Non-aggregating human VH domains |
| 01/05/2011 | CN101939025A Therapeutic agent for pruritus |
| 01/05/2011 | CN101938997A Patch with hydrophilic adhesive |
| 01/05/2011 | CN101938912A Prevention and treatment of otitis media using iga enriched milk |
| 01/05/2011 | CN101935687A Application of IL-12p40 siRNA to promoting liver regeneration |
| 01/05/2011 | CN101935637A Recombinant low-virulent vaccine strain of chicken infectious bursal disease viruses (IBDV) and application thereof |
| 01/05/2011 | CN101935353A Strepavidin/sCD40L fusion protein |
| 01/05/2011 | CN101935352A Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
| 01/05/2011 | CN101935349A Humanized monoclonal antibody against human vascular endothelial growth factor and preparation and application thereof |
| 01/05/2011 | CN101934077A Multivalent meningococcal derivatized polysaccharide-proteinconjugates and vaccine |